The company increased its offering to more than 23.3 million shares, exceeding the original target of nearly 21.7 million. By pricing the stock at the midpoint of its projected $14 to $16 range, Electra Therapeutics balanced investor demand with its capital requirements. Trading under the ticker ETRA, the stock makes its public debut following the conclusion of the pricing process late Thursday.
Electra Therapeutics Raises $350 Million in Upsized IPO
South San Francisco-based clinical-stage biopharmaceutical firm Electra Therapeutics is set to join the Nasdaq Global Select Market this Friday. The company finalized its upsized initial public offering at $15 per share, successfully securing $350 million in new capital to fuel its ongoing research and clinical development pipeline.
Comments (0)
No comments yet. Be the first!